Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

• Status: Recruiting
• Trial end date: 2032-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre
• Collaborators: Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination for the Improvement of Higher Education Personnel; Federal University of Rio Grande do Sul
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• White Brazilian of European descent

• Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD

• Eligibility to immediate-release MPH (IR-MPH) treatment

Exclusion Criteria:

• Contraindication for IR-MPH use

• Current stimulant treatment

• Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)

• Current or past history of psychosis

• Estimated intelligence quotient score lower than 70